SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
JUNE 15, 2001
-------------
(Date of Report)
ENTROPIN, INC.
--------------
(Exact Name of Registrant as specified in its charter)
Colorado 33-23693 84-1090424
- ---------------------------- ----------- -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
45926 OASIS STREET, INDIO, CALIFORNIA 92201
-------------------------------------------
(Address of principal executive offices including zip code)
(760) 775-8333
---------------
(Registrant's telephone number including area code)
N/A
---
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS.
- ---------------------
Entropin, Inc. ("Entropin") issued the following press release on
June 14, 2001:
NEWS RELEASE
-------------
ENTROPIN SELECTS CLINICAL SITES FOR ESTEROM PHASE II/III STUDY
INDIO, Calif. (JUNE 14, 2001) - ENTROPIN, INC. (NASDAQ: ETOP; ETOPW), a
specialty pharmaceutical company developing new therapeutics for painful
soft tissue injuries, today announced that the Company has contracted with
three clinical centers of excellence for the enrollment of patients in its
forthcoming Phase II/III trial for Esterom(R).
The trial, scheduled to start in the third quarter of 2001, will be
performed at The Cleveland Clinic, ProHealth Associates and Tampa Medical
Research Group. These sites were chosen for their expertise in
orthopaedics and in rheumatology.
Entropin commented that only proven professional clinical trial sites were
selected following in-depth evaluations of numerous organizations.
Discussions are underway with a potential fourth site, which may be added
to expedite patient enrollment.
The clinical trial, a double-blind, placebo-controlled Phase II/III pivotal
study, will treat 150 patients for shoulder pain and disability.
"Our previous Phase IIIA study was conducted at sites that perform clinical
trials on a wide range of pharmaceutical products," said Thomas G.
Tachovsky, Ph.D., Entropin's president and chief executive officer.
"Esterom(R) is a unique topical pharmaceutical designed to treat painful
soft tissue injuries, a pervasive but complex medical problem. We have
learned the importance of utilizing medical professionals who are experts
in these types of injuries for our clinical trials, and we have chosen
these sites with proven track records specifically for that reason."
THE CLEVELAND Clinic, founded in Cleveland, Ohio in 1921, integrates
clinical and hospital care with research and education, and has been named
one of the 10 best hospitals in the nation by U.S. News & World Report.
PROHEALTH ASSOCIATES, Lake Success, New York, is a large healthcare
delivery organization with a specialty in sports medicine. The group
includes 12 orthopaedic and rheumatology specialists.
THE TAMPA MEDICAL GROUP RESEARCH, Tampa, Florida, has conducted over 450
clinical trials evaluating drugs to treat the full range of orthopaedic and
rheumatologic disorders. Since 1978, the Tampa Medical Group has performed
numerous clinical trials for major pharmaceutical companies.
Entropin, Inc. is a pharmaceutical research and development company,
initially focused on the development of Esterom(R), a novel topical
therapeutic for the treatment of painful soft tissue injuries, such as
tendonitis or back sprain, that result in impaired function.
2
THIS NEWS RELEASE INCLUDES FORWARD-LOOKING STATEMENTS THAT REFLECT
ENTROPIN'S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND FINANCIAL
PERFORMANCE. THE WORDS "BELIEVE," "EXPECT," "ANTICIPATE," AND SIMILAR
EXPRESSIONS IDENTIFY FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING
STATEMENTS ARE SUBJECT TO A VARIETY OF RISKS, UNCERTAINTIES, AND OTHER
FACTORS THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE
EXPRESSED IN ANY SUCH FORWARD-LOOKING STATEMENTS. THESE FACTORS INCLUDE,
BUT ARE NOT LIMITED TO: (1) THE ABILITY TO SUCCESSFULLY COMPLETE
DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS, INCLUDING THE COST, SCOPE
AND RESULTS OF PRECLINICAL AND CLINICAL TESTING; (2) THE ABILITY TO
SUCCESSFULLY COMPLETE PRODUCT RESEARCH AND FURTHER DEVELOPMENT, INCLUDING
PRE-CLINICAL AND CLINICAL STUDIES; (3) THE TIME, COST AND UNCERTAINTY OF
OBTAINING REGULATORY APPROVALS; (4) THE ABILITY TO OBTAIN SUBSTANTIAL
ADDITIONAL FUNDING; (5) THE ABILITY TO DEVELOP AND COMMERCIALIZE PRODUCTS
BEFORE COMPETITORS; AND (6) OTHER FACTORS DETAILED FROM TIME TO TIME IN
FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION.
###
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: June 15, 2001 ENTROPIN, INC.
By /s/ Thomas G. Tachovsky
--------------------------------------
Thomas G. Tachovsky
President and Chief Executive Officer
3